Scholarlink

Background <p>In neuroendocrine tumors molecular imaging methods play a key role, either targeting the somatostatin receptor or catecholamine pathways. [<sup>18</sup>F]SiTATE is a somatostatin receptor-targeting peptide that uses silicon fluoride acceptor (SiFA) radiochemistry, overcoming disadvantages of Gallium-68 labelled DOTA compounds. Here we present the first prospective data of [<sup>18</sup>F]SiTATE compared to [<sup>18</sup>F]DOPA-PET in NET patients.</p> Methods <p>38 patients with suspected neuroendocrine tumors were prospectively included. All patients underwent both [<sup>18</sup>F]DOPA-PET and [<sup>18</sup>F]SiTATE-PET. The diagnostic performances were compared on a per-patient and per-lesion basis.</p> Results <p>22 of 38 patients did not show [<sup>18</sup>F]DOPA- or [<sup>18</sup>F]SiTATE-PET positive disease. [<sup>18</sup>F]DOPA-PET was rated as the more accurate imaging modality in three cases and [<sup>18</sup>F]SiTATE-PET in four cases. [<sup>18</sup>F]SiTATE-PET showed a significantly higher sensitivity on a per lesion basis compared to [<sup>18</sup>F]DOPA-PET (<i>n</i> = 143; sensitivity [<sup>18</sup>F]SiTATE: 86.7%; [<sup>18</sup>F]DOPA: 73.4%; <i>p</i> = 0.016). Relative quantitative uptake values were not significantly different ([<sup>18</sup>F]SiTATE median Tumor to Background Ratio max (TBR<sub>max</sub>): 8.2; [<sup>18</sup>F]DOPA TBR<sub>max</sub>: 6.5; <i>p</i> = 0.247).</p> Conclusions <p>In this first prospective study, [<sup>18</sup>F]SiTATE-PET provided high tumor to background ratios in the majority of NET patients with complementary results to [<sup>18</sup>F]DOPA-PET.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Head to head comparison of [18F]SiTATE versus [18F]DOPA-PET in patients with neuroendocrine tumors

  • 期刊论文

  • 发表日期：

    2025年9月26日

查看全文
  • Wolfgang Roll,
  • Panayiotis Hadjitheodorou,
  • Emmanouil Alevroudis,
  • Kyriaki Kyrou,
  • Giorgos Adamou,
  • Andreas Fesas,
  • Björn Wängler,
  • Carmen Wängler,
  • Ralf Schirrmacher,
  • Mohammad R. Pourkhessalian,
  • Charalambia Kalogirou,
  • Ioannis Tsechelidis,
  • Alexis Vrachimis

摘要

Background

In neuroendocrine tumors molecular imaging methods play a key role, either targeting the somatostatin receptor or catecholamine pathways. [18F]SiTATE is a somatostatin receptor-targeting peptide that uses silicon fluoride acceptor (SiFA) radiochemistry, overcoming disadvantages of Gallium-68 labelled DOTA compounds. Here we present the first prospective data of [18F]SiTATE compared to [18F]DOPA-PET in NET patients.

Methods

38 patients with suspected neuroendocrine tumors were prospectively included. All patients underwent both [18F]DOPA-PET and [18F]SiTATE-PET. The diagnostic performances were compared on a per-patient and per-lesion basis.

Results

22 of 38 patients did not show [18F]DOPA- or [18F]SiTATE-PET positive disease. [18F]DOPA-PET was rated as the more accurate imaging modality in three cases and [18F]SiTATE-PET in four cases. [18F]SiTATE-PET showed a significantly higher sensitivity on a per lesion basis compared to [18F]DOPA-PET (n = 143; sensitivity [18F]SiTATE: 86.7%; [18F]DOPA: 73.4%; p = 0.016). Relative quantitative uptake values were not significantly different ([18F]SiTATE median Tumor to Background Ratio max (TBRmax): 8.2; [18F]DOPA TBRmax: 6.5; p = 0.247).

Conclusions

In this first prospective study, [18F]SiTATE-PET provided high tumor to background ratios in the majority of NET patients with complementary results to [18F]DOPA-PET.